Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
68 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Haemophilus Influenzae Type b Infections - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Haemophilus Influenzae Type b Infections - Pipeline Review, H2 2014', provides an overview of the Haemophilus Influenzae Type b Infections's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Haemophilus Influenzae Type b Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Haemophilus Influenzae Type b Infections and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Haemophilus Influenzae Type b Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Haemophilus Influenzae Type b Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Haemophilus Influenzae Type b Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Haemophilus Influenzae Type b Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Haemophilus Influenzae Type b Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Haemophilus Influenzae Type b Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Haemophilus Influenzae Type b Infections Overview 8 Therapeutics Development 9 Pipeline Products for Haemophilus Influenzae Type b Infections - Overview 9 Pipeline Products for Haemophilus Influenzae Type b Infections - Comparative Analysis 10 Haemophilus Influenzae Type b Infections - Therapeutics under Development by Companies 11 Haemophilus Influenzae Type b Infections - Therapeutics under Investigation by Universities/Institutes 13 Haemophilus Influenzae Type b Infections - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Unknown Stage Products 17 Haemophilus Influenzae Type b Infections - Products under Development by Companies 18 Haemophilus Influenzae Type b Infections - Products under Investigation by Universities/Institutes 20 Haemophilus Influenzae Type b Infections - Companies Involved in Therapeutics Development 21 Beijing Minhai Biotechnology Co., Ltd 21 Biological E. Limited 22 Chongqing Zhifei Biological Products Co., Ltd. 23 GlaxoSmithKline plc 24 Indian Immunologicals Limited 25 LG Life Sciences, Ltd. 26 Novartis AG 27 Nuron Biotech, Inc. 28 Panacea Biotec Limited 29 Sanofi Pasteur SA 30 Sinovac Biotech Ltd. 31 Zydus Cadila Healthcare Limited 32 Haemophilus Influenzae Type b Infections - Therapeutics Assessment 33 Assessment by Monotherapy Products 33 Assessment by Combination Products 34 Assessment by Target 35 Assessment by Route of Administration 37 Assessment by Molecule Type 39 Drug Profiles 41 (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis + haemophilus influenza [serogroup B]) vaccine - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 diphtheria + pertussis + tetanus + hepatitis [serotype B] + haemophilus influenza [serotype B] vaccine - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 diphtheria + tetanus + pertussis (whole cell) + haemophilus influenzae [type B] + polio (pentavalent) vaccine - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 diphtheria + tetanus + pertussis (whole-cell) + haemophilus influenzae [serotype B] vaccine - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] vaccine - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + haemophilus influenzae [type B] (pentavalent) vaccine - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + poliomyelitis + haemophilus influenzae [type B] (hexavalent) vaccine - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 GSK-217744 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 haemophilus influenza [serotype B] vaccine - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 haemophilus influenzae [serotype B] + meningococcal polysaccharide [serotypes A, C, Y, W-135] vaccine - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 haemophilus influenzae [serotype B] vaccine - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 haemophilus influenzae [type B] vaccine - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 haemophilus influenzae conjugate vaccine [type B] - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 haemophilus influenzae type b oligosaccharide conjugate vaccine - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 haemophilus influenzae vaccine [type B] - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 hemophilus influenza [Type B] vaccine - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 NU-300 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Vaccine for Haemophilus Influenzae Type b Infections - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Haemophilus Influenzae Type b Infections - Recent Pipeline Updates 60 Haemophilus Influenzae Type b Infections - Dormant Projects 62 Haemophilus Influenzae Type b Infections - Product Development Milestones 63 Featured News & Press Releases 63 Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur's Investigational Pediatric Hexavalent Vaccine 63 Sep 26, 2013: Takeda Submits New Drug Application in Japan for TAK-816, a Haemophilus Influenzae type b vaccine 64 Apr 22, 2013: Sanofi Obtains European Approval For Six-in-One Pediatric Vaccine Hexyon/Hexacima 64 Feb 22, 2013: Sanofi Pasteur Announces EMA's CHMP Recommends Approval Of Hexyon/Hexacima Six-In-One Pediatric Vaccine 65 Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Paediatric Vaccine In European Markets 66 Appendix 67 Methodology 67 Coverage 67 Secondary Research 67 Primary Research 67 Expert Panel Validation 67 Contact Us 68 Disclaimer 68
List of Tables Number of Products under Development for Haemophilus Influenzae Type b Infections, H2 2014 9 Number of Products under Development for Haemophilus Influenzae Type b Infections - Comparative Analysis, H2 2014 10 Number of Products under Development by Companies, H2 2014 12 Number of Products under Investigation by Universities/Institutes, H2 2014 13 Comparative Analysis by Late Stage Development, H2 2014 14 Comparative Analysis by Clinical Stage Development, H2 2014 15 Comparative Analysis by Early Stage Development, H2 2014 16 Comparative Analysis by Unknown Stage Development, H2 2014 17 Products under Development by Companies, H2 2014 18 Products under Investigation by Universities/Institutes, H2 2014 20 Haemophilus Influenzae Type b Infections - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2014 21 Haemophilus Influenzae Type b Infections - Pipeline by Biological E. Limited, H2 2014 22 Haemophilus Influenzae Type b Infections - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H2 2014 23 Haemophilus Influenzae Type b Infections - Pipeline by GlaxoSmithKline plc, H2 2014 24 Haemophilus Influenzae Type b Infections - Pipeline by Indian Immunologicals Limited, H2 2014 25 Haemophilus Influenzae Type b Infections - Pipeline by LG Life Sciences, Ltd., H2 2014 26 Haemophilus Influenzae Type b Infections - Pipeline by Novartis AG, H2 2014 27 Haemophilus Influenzae Type b Infections - Pipeline by Nuron Biotech, Inc., H2 2014 28 Haemophilus Influenzae Type b Infections - Pipeline by Panacea Biotec Limited, H2 2014 29 Haemophilus Influenzae Type b Infections - Pipeline by Sanofi Pasteur SA, H2 2014 30 Haemophilus Influenzae Type b Infections - Pipeline by Sinovac Biotech Ltd., H2 2014 31 Haemophilus Influenzae Type b Infections - Pipeline by Zydus Cadila Healthcare Limited, H2 2014 32 Assessment by Monotherapy Products, H2 2014 33 Assessment by Combination Products, H2 2014 34 Number of Products by Stage and Target, H2 2014 36 Number of Products by Stage and Route of Administration, H2 2014 38 Number of Products by Stage and Molecule Type, H2 2014 40 Haemophilus Influenzae Type b Infections Therapeutics - Recent Pipeline Updates, H2 2014 60 Haemophilus Influenzae Type b Infections - Dormant Projects, H2 2014 62
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.